Evidence map›Paper›PMID 22911109›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2012

Genetic driver events in premalignancy: LOH validated for marking the risk of oral cancer.

Webster K Cavenee

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Webster K CaveneeLudwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA, USA. wcavenee@ucsd.edu
Ludwig Cancer Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue of the journal (beginning on page 1081), Zhang and colleagues extend the 30-year-old discovery of LOH profiles to provide validated markers of oral premalignant lesion risk for cancer. They prospectively show a dramatic difference in cancer progression between high-risk lesions (LOH) and low-risk (non-LOH) lesions (P = 0.002). This work has important implications for oral cancer prevention and risk modeling and for understanding genetic driver events in premalignancy.

Indexed as

FemaleHumansLoss of HeterozygosityMaleMouth NeoplasmsPrecancerous Conditions

Identifiers

PMID22911109
OpenAlexW2158831102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.